ArticleAnnals of gastroenterological surgery2023
Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer.
Article in Annals of gastroenterological surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Survival benefit of conversion surgery for initially unresectable biliary tract cancer: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- Survival Outcomes of Gemcitabine-Cisplatin-S-1 Versus Gemcitabine-Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery.Annals of gastroenterological surgery · 2026Article
- A case of perihilar cholangiocarcinoma with peritoneal dissemination that achieved a pathological complete response using immune checkpoint inhibitors: A case report.International cancer conference journal · 2026Article
- Article
- Pathological Complete Response after Conversion Surgery for Distal Cholangiocarcinoma with High Tumor Mutational Burden and Para-Aortic Lymph Node Metastasis: A Case Report.Surgical case reports · 2026Article
- A Case of Unresectable Ampulla of Vater Carcinoma Successfully Treated with Conversion Surgery Following Sequential Systemic Chemotherapy Including Durvalumab.Surgical case reports · 2026Article
- Utility of a novel sheath designed for mapping biopsy for preoperative malignant hilar biliary obstruction.Endoscopy international open · 2026Article
- A Case of Pathological Complete Response after "Conversion Surgery" for Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma.Surgical case reports · 2026Article
- Revisiting resectability of biliary tract cancers, in the triplet drug therapy era with immune checkpoint inhibitors.International journal of clinical oncology · 2025Review
- Durvalumab-combined chemotherapy for biliary tract cancer in a Japanese expert center: initial 50 cases in daily practice.Nagoya journal of medical science · 2025Article
- A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.Clinical journal of gastroenterology · 2025Article
- Conversion Surgery after Complete Response to Immune Checkpoint Inhibitor-Based Sequential Chemotherapy for Initially Unresectable Perihilar Cholangiocarcinoma: A Case Report.Surgical case reports · 2025Article
- Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report.World journal of clinical cases · 2024Article
- Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes.Journal of gastrointestinal cancer · 2024Article
- Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer.Annals of gastroenterological surgery · 2023Article
- Pathological Complete Response following Pembrolizumab Combined with Gemcitabine and Cisplatin Therapy for Initially Unresectable Intrahepatic Cholangiocarcinoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gemcitabine, cisplatin, and S-1 chemotherapy was superior to gemcitabine and cisplatin chemotherapy for progression-free survival and overall survival for unresectable and recurrent biliary tract cancer in a randomized phase III trial (KHBO1401). This study aimed to evaluate the outcome of conversion surgery after chemotherapy in biliary tract cancer patients (ancillary study, KHBO1401-3C). Methods: A total of 246 patients were enrolled in KHBO1401. We compared progression-free and overall survivals between the conversion surgery and non-conversion surgery groups. Results: Eight patients (3.3%) underwent conversion surgery with chemotherapy, seven of whom were diagnosed with unresectable disease and one with recurrence. Six and two patients received gemcitabine, cisplatin, and S-1 chemotherapy as well as gemcitabine and cisplatin chemotherapy, respectively. Three patients in the conversion surgery group who received gemcitabine, cisplatin, and S-1 chemotherapy showed no disease progression and survived without postoperative chemotherapy. Preoperative carbohydrate antigen 19-9 (CA19-9) level was a prognostic factor for conversion surgery. After correcting for immortal time bias, 1-year progression-free survival rates in the conversion surgery and non-conversion surgery groups were 50.0% and 19.0%, respectively (hazard ratio 0.343, 95% confidence interval 0.286-0.843, Conclusions: Conversion surgery might be an option for the treatment of unresectable and recurrent biliary tract cancer in patients with normal preoperative CA19-9 level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.